CanSino Biologics (HKG:6185, SHA:688185) said it has initiated a Phase 1 clinical trial for its DTcP-Hib-MCV4 combined vaccine and has completed enrollment of the first patient, according to a Dec. 19 Hong Kong bourse filing.
Shares of the firm were up more than 1% in Monday morning trade.
The Phase 1 study is designed to evaluate the safety and immunogenicity of the vaccine in subjects aged between two months and six years, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments